-Andrew D Luster Researcher Activity Profile

Research Author Detailed Information 

Andrew D Luster Publication Rate By Year

Andrew D Luster has published 3 paper(s) in 2007, 14 paper(s) in 2008, for a total of 17 research publications in total.

Andrew D Ad Luster Author Information

LAST NAME: luster

FIRST NAME: Andrew D

INITIALS: ad

AFFILIATION:

Papers

Andrew D Luster's Publication Record

1. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Year Published: 2007
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, Massachusetts 02129, USA. jelkhoury@partners.org
2. CCR4-dependent regulatory T cell function in inflammatory bowel disease. Year Published: 2007
Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
3. CCR4-dependent regulatory T cell function in inflammatory bowel disease. Year Published: 2007
Division of Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
4. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Year Published: 2008
Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA.
5. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Year Published: 2008
Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
6. Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from austria with lyme borreliosis. Year Published: 2008
1Division of Rheumatology, Allergy, and Immunology, Center for Immunology and Inflammatory Diseases, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; and 2Department of Dermatology, Medical University of Graz, Graz, Austria.
7. An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain. Year Published: 2008
8. Higher mRNA levels of chemokines and cytokines associated with macrophage activation in erythema migrans skin lesions in patients from the United States than in patients from Austria with Lyme borreliosis. Year Published: 2008
Division of Rheumatology, Allergy, and Immunology, Center for Immunology and Inflammatory Diseases, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. kljones@partners.org
9. An ectromelia virus protein that interacts with chemokines through their glycosaminoglycan binding domain. Year Published: 2008
10. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Year Published: 2008
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, CNY149-8301, 149 13th Street, Charlestown, Massachusetts 02129 USA.
11. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Year Published: 2008
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA.
12. Development of a novel chemokine-mediated in vivo T cell recruitment assay. Year Published: 2008
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, 02129, USA.
13. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Year Published: 2008
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, CNY149-8301, 149 13th Street, Charlestown, Massachusetts 02129 USA.
14. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Year Published: 2008
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129.
15. Chemokines and their receptors: drug targets in immunity and inflammation. Year Published: 2008
Istituto Clinico Humanitas IRCCS, 20089 Rozzano, Milan, Italy. antonella.viola@humanitas.it
16. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Year Published: 2008
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA.
17. Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Year Published: 2008
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.